Biosynex SA (FRA:0DL)

Market Cap	17.14M -29.1%
Revenue (ttm)	95.19M -5.9%
Net Income	-58.22M
EPS	-3.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.8720
Previous Close	0.8900
Day's Range	0.8720 - 0.8720
52-Week Range	0.4630 - 1.6050
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2026

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products, as well as anti-mosquito bracelets and waterproof, moisturizi...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2005
• Employees: 397
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0DL

Financial Performance

In 2025, Biosynex's revenue was 95.19 million, a decrease of -5.90% compared to the previous year's 101.17 million. Losses were -58.22 million, 34.4% more than in 2024.